Docetaxel is effective in the treatment of metastatic endometrial cancer

Anticancer Research

Volumn 19, Issue 4 C, 1999, Pages 3459-3461

  Günthert, Andreas R ^a   Pilz, Sonja ^a   Kuhn, Walther ^a   Emons, Günter ^a   Meden, Harald ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Chemotherapy; Docetaxel; Endometrial carcinoma; Metastases

Indexed keywords

DOCETAXEL; EPIRUBICIN;

AGED; ARTICLE; ASTHENIA; CANCER INHIBITION; CANCER REGRESSION; CASE REPORT; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; HUMAN; LUNG METASTASIS; PARESTHESIA; PRIORITY JOURNAL; SKIN ALLERGY;

ADENOCARCINOMA; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ENDOMETRIAL NEOPLASMS; EPIRUBICIN; FEMALE; HUMANS; LUNG NEOPLASMS; PACLITAXEL; TAMOXIFEN; TAXOIDS; TUMOR MARKERS, BIOLOGICAL;

EID: 0343986526     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Neijt JP: Advances in the chemotherapy of gynecologic cancer. Curr Opin Oncol 6: 531-538, 1994.
2. Greven KM, Corn BW: Endometrial cancer. Curr Probl Cancer 21: 65-127, 1997.
3. Eisenhauer EA, Vermorken JB: New drugs in gynecologic oncology. 8: 408-414, 1997.
4. Wang TH, Wang HS, Ichijo H, Giannakakou P, Foster JS, Fojo T, Wimalasena J: Microtubule-interfering agents activate c-Jun N-terminal kinase/stress-activated protein kinase through both ras and apoptosis signal- regulating kinase pathways. J Biol Chem 273: 4928-4936, 1998.
5. Mc Guire WP, Hoskins WJ, Brady MF, Kucera PR: A phase III trial comparing cisplatin/cyclophosphamide (PC) and cisplatin/ paclitaxel (PT) in advanced ovarian cancer. N Engl J Med 334: 1-6, 1996.
6. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, Van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314-322, 1995.
7. Moos PJ, Fitzpatrick FA: Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 95: 3896-3901, 1998.
8. Yu D, Liu B, Jing T, Sun D, Price JE, Singletary SE, Ibrahim N, Hortobagyi GN, Hung MC: Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene 16: 2087-2094, 1998.
9. Rantanen V, Grenman S, Kulmala J, Grenman R: Endometrial cancer cell lines are sensitive to paclitaxel. Anticancer Res 16: 475-9, 1996.
10. Lissoni A, Gabriele A, Gorga G, Tumolo S, Landoni F, Mangioni C, Sessa C: Cisplatin-, epirubicin- and paclitaxel-containing chemotherapy in uterine adenocarcinoma. Ann Oncol 8: 969-72, 1997.
11. Price FV, Edwards RP, Kelley JL, Kunschner AJ, Hart LA: A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin Oncol 24: S 15-78-S 15-82, 1997.
12. Panday VRN, Huizing MT, Ten-Bokkel HWW, Vermorken JB, Beijnen JH: Hypersensitivity reactions to the taxanes paclitaxel and docetaxel. Clin Drug Invest 14: 418-427, 1997.
13. Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco FA: Phase 1 trial docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16: 2164-2168, 1998.